Dailymed elahere
WebNov 15, 2024 · Most patients will receive three to four vials of Elahere per treatment cycle, putting the cost at about $18,500 to $25,000 a cycle, Immunogen Chief Executive Mark Enyedy said on a conference call. WebMar 5, 2024 · Elahere (mirvetuximab soravtansine-gynx) is a prescription drug used to treat ovarian cancer. Learn about its uses, cost, dosage, side effects, and more.
Dailymed elahere
Did you know?
WebConnect with an ELAHERE Support Services Program specialist. Phone: 1-833-ELAHERE. ( 1-833-352-4373 ) Monday to Friday, 8:00 am to 8:00 pm ET. Email: [email protected]. BACK TO TOP. … WebThe drug labels and other drug-specific information on this Web site represent the most recent drug listing information companies have submitted to the Food and Drug Administration (FDA). (See 21 CFR part 207.) The drug labeling and other information has been reformatted to make it easier to read but its content has neither been altered nor ...
WebELAHERE Support Services is committed to helping appropriate patients start on ELAHERE by offering access and reimbursement support as well as affordability assistance. For more information, call the ELAHERE Support Services Program at 1-833-ELAHERE (1-833-352-4373) Monday to Friday, 8:00 am to 8:00 pm ET ELAHERE BILLING AND CODING GUIDE Web• Administer ELAHERE as an intravenous infusion only after dilution in 5% Dextrose Injection, USP. ELAHERE is incompatible with normal saline. (2.5) • The recommended dose of ELAHERE is 6 mg/kg adjusted ideal body weight administered as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. ( 2.2)
WebMirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for fallopian tube cancer or primary peritoneal cancer. Mirvetuximab … WebNov 14, 2024 · On November 14, 2024, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) …
WebELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer responding to treatment with platinum-based chemotherapy and. have received 1 to 3 prior types of chemotherapy.
WebNov 17, 2024 · About: Mirvetuximab soravtansine-gynx (Elahere™) Mirvetuximab soravtansine-gynx is a type of monoclonal antibody. It is a medicine designed to target a specific protein or cell – in this case, the target is a folate receptor alpha. This medication is also a microtubule inhibitor conjugate. the phoenix deluxe edition lp greyWebElahere (mirvetuximab sorvtansine-gynx) Requests for Elahere (mirvetuximab sorvtansine-gynx) may be approved if the following criteria are met: I. Individual has a diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer; the phoenix davenport iaWebELAHERE is an ADC that binds to tumor surface receptor FRα. Upon binding to the FRα receptor, ELAHERE is internalized into the cell. This prompts intracellular release of DM4, a potent cytotoxic tubulin inhibitor, resulting in cell death. DM4 diffuses across the cell membrane and kills neighboring cells (bystander killing)†. the phoenix device reviewWebSep 15, 2024 · DailyMed contains labeling for prescription and nonprescription drugs for human and animal use, and for additional products such as medical gases, devices, … the phoenix delrayWebNov 15, 2024 · Among 106 patients, the objective response rate on Elahere by investigator assessment was 31.7 percent, including five complete responses. The median duration of response was 6.9 months. ImmunoGen used Roche's assay to select patients who received treatment in the trial. Full approval of Elahere is contingent upon a confirmatory trial. the phoenix destiny 2WebELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not … the phoenix detroitWebMar 1, 2024 · Elahere Injection Dosage and Administration Patient Selection. Select patients for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer with ELAHERE … the phoenix destin